---

Background and Objective: Breast cancer is one of the most important malignant tumors world -wide and the second common cancer in the females. Breast cancer is associated with a number of environmental factors and genetic damages. Ki67 is a proto-oncogene which is activated in cell proliferation process. Ki67 is important in prognosis and response to chemotherapy. The aim of this study was to investigate the Ki67 gene expression in patients with breast cancer by immunohistochemistry method. Materials and Methods: This descriptive laboratory study was conducted on 80 breast cancer specimens from patients admitted to the hospitals in Sabzevar, Iran during 2005-09. Samples were fixed in formalin, the tissue processing was done and sections were stained by Hematoxilin and Eosin method. The malignancy was diagnosed by two pathologists blindly. Over expression of ki67 was determined with the immunohistochemistry method. Slides were scored into negative, weak, average and strong based on percentage of cells which were stained. The Data were analyzed by SPSS-11.5, Chi-Square and Fisher’s exact tests. Results: Ki67 proliferative marker was observed in 37 (46.3%) specimens with breast cancer. Sensivity of staining was one positive (+) in 15 cases, two positive (++) in 14 cases and three positive (+++) in 8 cases. There was a significant relationship between Ki67 gene expression and tumor type and tumor staging (P<0.05), but there was no significant relationship between Ki67 gene expression and tumor grade. Conclusion: It is concluded that, ki67 is expressed mostly in invasive and developed breast cancer.

---

Background and Objective: Glycodelin expression in normal and cancerous human breast tissue and its relation with age, tumor type, microscopic grade and metastasis to axillary lymph nodes recently were noticed. This study was done to evaluate the glycodelin expression in breast cancer. Methods: In this descriptive study, 96 Paraffin-embedded blocks of malignant breast cancer by immunohistochemistry method were considered to evaluate the expression of glycodelin. Patients age,tumor size, tumor type, microscopic grade and metastasis to axillary lymph nodes were recorded for each subject. Results: Glycodelin was found in 30.45% of invasive carcinoma of the breast with axillary lymph node metastasis. Glycodelin was expressed in 72.7% of carcinoma of the breast without lymph nodes metastasis (P<0.05). There was a significant relation between glycodelin expression with microscopic grade 1 of tumor and metastasis to less than 4 of lymph nodes (P<0.05). Conclusion: Glycodelin expression can be evidence for lack of axillary lymph node metastasis of breast cancer.